Soaring U.K. energy costs top drug manufacturers concerns; Canada cuts OTC red tape;

 @EricPFierce: Genzyme says the FDA and EMA have signed off a second fill-finish operation for a couple of drugs at the upgraded plant in Ireland. Report | Follow @EricPFierce

> Soaring energy costs in the U.K. top the list of concerns for drug and chemical manufacturers there, according to a survey by a trade association. Story

> The U.K.'s Medicines and Healthcare products Regulatory Agency says it has a new plan for protecting consumers and fighting counterfeit drugs from getting into the authorized supply chain. News

> Almac has installed a blister line at its new plant in Audobon, PA. that is capable of producing 12,000 blister packs an hour in a series of sizes. Item

> Canada is eliminating a regulatory process, which will cut about a year out of the time it takes to move a branded drug to over-the-counter designation after its been given approval. More

> AMRI is expanding its contract manufacturing and outsourcing efforts. Article

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.